Neuronetics Q3 2026 slides: margins expand as profitability nears
Neuronetics Inc. (STIM) reported Q3 2026 revenue of $42.0M, up 12.5% YoY, with positive operating income of $0.5M. Gross margin expanded to 52.2%, and adjusted EBITDA improved to $1.9M. The company treats 29.3M Americans with depression and related conditions, offering TMS and esketamine therapies. CEO Dan Reuvers attributed results to record NeuroStar system sales and clinic strength. Future growth includes psychedelic therapies pending FDA approval.
How this was made
The 30-second read
Why it matters
Operating income turned positive, gross margin rose 630 bps, and share price jumped 16.8%, indicating strong market reaction.
Market read
First‑time earnings disclosure with profit and margin expansion, driving a notable share rally.
What to watch
Potential regulatory scrutiny of psychedelic‑therapy expansion and reliance on insurance reimbursement.
Background
Neuronetics provides TMS therapy systems and operates mental‑health clinics; Q3 2026 results show a turnaround from loss to profit.
Ticker impact
Neuronetics reported Q3 2026 revenue of $42M, positive operating income and 16.8% share surge.
upward as profitability improves and margin expansion drives investor optimism
First report of earnings with operating profit, margin expansion, and strong share reaction indicates fresh buying pressure.
Market effects
Mental‑health device and clinic operators may see valuation uplift as Neuronetics demonstrates scalable profitability.
U.S. biotech and med‑tech stocks could benefit from the earnings beat.
Limited to U.S. listed mental‑health technology niche.
Counterpoint
Margin gains may be temporary; competition from emerging TMS providers could pressure future growth.
Key entities
- CompanyNeuronetics Inc.
NASDAQ‑listed provider of TMS therapy systems and mental‑health clinics.
- ExecutiveDan Reuvers
CEO of Neuronetics who commented on the results.
